RESUMEN
OBJECTIVE:To explore the pharmacoeconomic effect of Ginkgo dipyidamolum,argatroban or sodium ozagerl combined with edaravone in the treatment of acute cerebral infarction(ACI). METHODS:In retrospective study,64 ACI patients were divided into group A(Ginkgo dipyidamolum+edaravone,22 cases),group B(argatroban+edaravone,19 cases)and group C (sodium ozagerl+edaravone,23 cases). Therapeutic efficacies were observed after 7-14 days of treatment;therapy cost was calculat-ed,and cost-minimization analysis was used to evaluate pharmacoeconomics. RESULTS:There was no statistical significance in to-tal effective rate among 3 groups(P>0.05);the costs of group A,group B and group C were 8 746.36 yuan,10 770.64 yuan and 8 264.67 yuan. Results of sensitivity analysis were in line with those of cost-minimization analysis. CONCLUSIONS:Therapy plan of sodium ozagerl+edaravone is the economical regime in the treatment of ACI .
RESUMEN
OBJECTIVE:To evaluate the status quo and tendency of the use of Chinese material medical injection(CMMI) in Nanjing area.METHOD:Chinese material medica injection used in 22 hospital of Nanjing from 2004 to 2006 was analyzed statistically in terms of variety,consumption sum,defined daily dose(DDDs) etc. RESULTS: The consumption sum of CMMI increased year by year,with annual incremental rates of 19.80% and 11.82% respectively.The cardio-cerebral vascular CMMI dominated the first place in terms of consumption sum and DDDs over the 3 years.Lentinan,Shengmai,Shenmai,Puerarin took the lead in consumption sum of single variety.The variety and specification and the number of manufacturers of CMMI increased year by year.CONCLUSION:CMMI plays a key role in clinical treatment,its consumption sum and consumption quantity kept increasing rapidly.